2023
DOI: 10.1245/s10434-023-13271-3
|View full text |Cite
|
Sign up to set email alerts
|

Editorial on: Moving Beyond Anatomic Criteria for Resectability: Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…The resectability status of pancreatic cancer was evaluated according to the 7th edition of the General Rules for the Study of Pancreatic Cancer, published by the Japan Pancreas Society [19]. Patients diagnosed with resectable (n = 5), borderline resectable (n = 29), and locally advanced unresectable pancreatic cancers (n = 1) underwent preoperative therapy with various regimens, such as gemcitabine plus nab-paclitaxel (n = 24), modi ed FOLFIRINOX (5-uorouracil, leucovorin, irinotecan, and oxaliplatin) (n = 2), gemcitabine plus S-1 (n = 8), or chemoradiotherapy with S-1 (n = 1).…”
Section: Treatment For Pancreatic Cancermentioning
confidence: 99%
“…The resectability status of pancreatic cancer was evaluated according to the 7th edition of the General Rules for the Study of Pancreatic Cancer, published by the Japan Pancreas Society [19]. Patients diagnosed with resectable (n = 5), borderline resectable (n = 29), and locally advanced unresectable pancreatic cancers (n = 1) underwent preoperative therapy with various regimens, such as gemcitabine plus nab-paclitaxel (n = 24), modi ed FOLFIRINOX (5-uorouracil, leucovorin, irinotecan, and oxaliplatin) (n = 2), gemcitabine plus S-1 (n = 8), or chemoradiotherapy with S-1 (n = 1).…”
Section: Treatment For Pancreatic Cancermentioning
confidence: 99%